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Abstract: Zinc finger AN1-type containing 4 (ZFAND4) has emerged as a promising prognostic
marker and predictor of metastasis for patients with oral squamous cell carcinoma (OSCC).
However, further validation is fundamental before clinical implementation. Hence, this study
evaluated the expression pattern of ZFAND4 protein expression by immunohistochemistry using an
independent cohort of 125 patients with OSCC, and correlations with the clinicopathologic parameters
and disease outcome. Remarkably, ZFAND4 expression, while negligible in normal epithelium,
exhibited two distinct expression patterns in tumors that did not overlap. A gross granular staining
was characteristic of the undifferentiated cells at the invasive front of tumors, whereas the most
differentiated cells located at the center of the tumor nests showed diffuse non-granular staining.
ZFAND4 staining was higher in undifferentiated than in differentiated areas of tumors. High ZFAND4
expression in differentiated cells was significantly associated to well-differentiated (p = 0.04) and
non-recurrent tumors (p = 0.04), whereas ZFAND4 expression in undifferentiated cells correlated with
tumor location (p = 0.005). No correlations between the ZFAND4 expression and patient survival were
found. These data question the clinical relevance of ZFAND4 expression as a prognostic biomarker in
OSCC, and also reveal distinct ZFAND4 expression patterns depending on the differentiation areas
of tumors that should be evaluated separately.
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1. Introduction
Head and neck squamous cell carcinoma that includes, among others, oral squamous cell
carcinoma (OSCC) is the sixth most common cancer in the world, with an annual prevalence of
nearly 600,000 new cases worldwide [1,2]. It is generally accepted that OSCC initiates and progresses
through a series of multiple genetic alterations caused by chronic exposure to carcinogens, such as
alcohol, smoking, and human papilloma virus [3]. Multiple genetic and molecular studies have
improved our understanding of the molecular basis of this disease. Indeed, several cellular signaling
pathways have been found dysregulated in these tumors through genetic and epigenetic alterations.
However, despite major advances in diagnosis and treatment, the survival rate of patients with OSCC
has modestly improved over the past 40 years, and it remains at approximately 50% [4].
Sasahira et al. [5] investigated the transcriptional profiles of primary and recurrent OSCC, and
found that one of the most upregulated genes identified in recurrent OSCC was zinc finger AN1-type
containing 4 (ZFAND4), also known as AN1 and ubiquitin-like homolog (ANUBL1). Although the
functional role of ZFAND4 in cancer is still unknown, Kurihara-Shimomura et al. [6] evaluated its
prognostic utility in OSCC. They concluded that ZFAND4 could be a useful marker for predicting
metastasis and poor prognosis in patients with OSCC. In addition, Tang et al. [7] demonstrated that
ZFAND4 expression is upregulated in gastric cancer and positively associated with the grading of
this disease.
In the light of these data, ZFAND4 emerges as a promising prognostic biomarker;
however, further validation in independent study cohorts is fundamental for implementation to
the clinic. Therefore, the objective of this study was to investigate the expression pattern and clinical
relevance of ZFAND4 protein expression using an independent cohort of 125 patients with OSCC,
and to establish correlations with the clinicopathologic parameters and disease outcome.
2. Experimental Section
2.1. Patients and Tissue Specimens
A retrospective study was designed. Surgical tissue specimens from 125 patients with OSCC who
underwent surgical treatment with curative purposes at the Hospital Universitario Central de Asturias
between 1996 and 2007 were retrospectively collected, in accordance to approved institutional review
board guidelines. All experimental procedures were conducted in accordance to the Declaration of
Helsinki and approved by the Institutional Ethics Committee of the Hospital Universitario Central
de Asturias and by the Regional CEIC from Principado de Asturias. Informed consent was obtained
from all patients. Clinicopathologic data were collected from medical records. Tissue specimens
were obtained from the Biobanco del Principado de Asturias, and representative tissue sections from
archival, formalin-fixed paraffin-embedded blocks.
2.2. Tissue Microarray Construction
The original archived hematoxylin- and eosin-stained slides were reviewed by an experienced
pathologist (FDI) to confirm histological diagnosis. Three representative tissue cores (1 mm diameter)
were selected from each tumor block, and transferred to a recipient ‘Master’ block in a grid-like manner
using a manual tissue microarray instrument. In addition, each tissue microarray also contained three
cores of normal epithelium as an internal control. A section from each microarray was stained with
hematoxylin and eosin, and examined by light microscopy to check the adequacy of tissue sampling.
2.3. Immunohistochemistry (IHC)
TMA sections (4 µm) were cut and dried and dried on Flex IHC microscope slides (Dako).
The sections were deparaffinized with standard xylene, hydrated through graded alcohols into water,
and pretreated by hydrogen peroxide to quench the endogenous peroxidase activity. Antigen retrieval
was performed using Envision Flex Target Retrieval solution (Dako), at room temperature on an
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automatic staining workstation (DakoAutostainer Plus, Dako, Glostrup, Denmark). Staining was
carried out at room temperature on an automatic staining workstation (Dako Autostainer Plus) with
anti-ZFAND4 antibody (Atlas Antibodies, Stockholm, Sweden) diluted to 0.5 Nµg/mL using the
Dako EnVision detection system (Dako, Glostrup, Denmark). Sections were counterstained with
hematoxylin, dehydrated with ethanol, and permanently coverslipped. For negative control purposes,
DakoCytomation mouse serum diluted at the same concentration as the primary antibody was used.
Staining was scored blinded to clinical data by two independent observers. ZFAND4 expression
was evaluated according to the percentage of stained tumor cells and the staining intensity using the
Allred score, as previously described [8]. The proportion of ZFAND4-positive cells was evaluated in
both undifferentiated and differentiated areas of the tumors. In all these groups, proportional scores
were categorized as: 0, no cells were stained; 1, 1/100 cells were stained; 2, 1/10 cells were stained;
4, 2/3 cells were stained; 5, all cells were stained. Staining intensity was scored as: 0, negative; 1, weak;
2, intermediate; and 3, strong. The total score was calculated by the sum of the proportional and
intensity scores, ranging from 0 to 8. Similar to Kurihara-Shimomura et al. [6], the optimal cut-off
score for ZFAND4 expression was selected using the receiver operating characteristic (ROC) curve
according to the survival status. ZFAND4 staining was independently evaluated in undifferentiated
areas of tumors mainly located at the invasive front, and in differentiated areas at the center of the
tumor islands.
2.4. Statistical Analysis
χ2 and the Fisher’s exact test were used for comparison between categorical variables.
Disease-specific survival (DSS) was determined for the date of treatment completion to death for
the tumor. For time-to-event analysis, survival curves were plotted using the Kaplan-Meier method.
Differences between survival times were analyzed by the log-rank test. Hazard ratios (HR) with their
95% confidence intervals (CI) for clinicopathologic variables were calculated using the univariate
Cox proportional hazards model analysis. All tests were two-sided and p values less than 0.05
were considered statistically significant. All statistical analyses were performed using SPSS version
21 (IBM Co., Armonk, NY, USA).
3. Results
3.1. Patient Characteristics
The cohort of 125 OSCC patients was composed of 82 men and 43 women, ranging from 28 to
91 years, with a median age of 57 years. Forty-one patients (33%) were never-smokers and 56 (45%)
never-drinkers. The main clinicopathologic characteristics are summarized in Table 1. Forty-nine
cases (39%) showed neck lymph node metastasis, more than 50% were well-differentiated tumors
and advanced clinical stages (III or IV), and the most common site was the tongue (41%) followed
by the floor of the mouth (30%). Adjuvant radiotherapy was administered to 75 patients (60%),
and adjuvant chemotherapy to 14 patients (11.2%). Fifty-four cases (43%) showed loco-regional
recurrence, and 19 (15%) suffered from a second primary carcinoma. Over a median follow-up of
61 months (range, 1 to 230 months) 53 deaths occurred.
Table 1. Clinical and pathological characteristics of 123 patients with oral squamous cell carcinoma
and where zinc finger AN1-type containing 4 (ZFAND4) was valuable.
Variable Number (%)
Age (year) (mean ± SD; median; range) 58.6 ± 14.3; 57; 28–91
Gender
Men 81 (66)
Women 42 (34)
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Table 1. Cont.
Variable Number (%)
Tobacco use
Smoker 83 (67)
Non-smoker 40 (33)
Alcohol use
Drinker 68 (55)
Non-drinker 55 (45)
Location of oral squamous oral cell carcinoma
Tongue 51 (41)
Floor of the mouth 35 (28)
Other sites within te oral cavity 37 (31)
Tumor status
pT1 27 (22)
pT2 53 (43)
pT3 15 (12)
pT4 28 (23)
Nodal status
pN0 74 (60)
pN1 25 (20)
pN2 24 (20)
Clinical stage
Stage I 20 (16)
Stage II 31 (25)
Stage III 25 (20)
Stage IV 47 (39)
G status
G1 78 (63)
G2 41 (33)
G3 4 (4)
Second primary carcinoma
No 104 (85)
Yes 19 (15)
Local recurrence
No 69 (56)
Yes 54 (44)
Clinical status at the end of the follow-up
Live and without recurrence 51 (41)
Dead of index cancer 53 (43)
Lost or died of other causes (censored) 19 (16)
3.2. Immunohistochemical Analysis of ZFAND4 Expression in OSCC Tissue Specimens
ZFAND4 staining was not valuable in two (1.6%) of 125 OSCC specimens. While ZFAND4
expression was negligible in normal epithelium, two distinct expression patterns were noted in
the tumors that did not overlap in any of the samples (Figure 1). A gross granular staining
was characteristic of the undifferentiated cells at the invasive front of tumors, whereas the most
differentiated cells located at the center of the tumor nests showed diffuse non-granular staining.
The mean percentages of positive ZFAND4 staining were 44.98 (standard deviation –SD-35.38) in
undifferentiated cells and 17.18 (SD, 20.61) in differentiated cells. ZFAND4 staining intensity was
also evaluated in both undifferentiated and differentiated areas. In undifferentiated cells, there were
13 (11%) negative cases, 37 (30%) weak, 43 (35%) intermediate, and 30 (24%) cases with strong staining.
In differentiated cells, 47 (38%) cases were scored negative, 11 (9%) weak, 47 (38%) intermediate,
and 18 (15%) had strong staining. Since each tumor was represented by three different tissue
cores in the OSCC TMAs, the percentages of stained cells frequently varied in the three tumor
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areas assessed. Taking this into consideration, the Allred score was determined in two different
ways: Either considering the maximum value of ZFAND4 positivity or the mean value of the
three tumor cores. Regarding the intensity of immunostaining, the maximum value was always
used for all calculations. Finally, the total score was calculated by the sum of the percentages of
staining and intensity scores. The resulting indexes ranged between 0 and 8. The receiver operating
characteristics (ROC) curve was used to determine the best cut-off score to predict patients’ survival,
and this value was 4. Accordingly, those cases with an Allred score above 4 were considered as high
ZFAND4 expression.
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Figure 1. Immunoexpression of ZFAND4 in oral squamous cell carcinoma. (A) Staining in undifferentiated
areas (arrow) and differentiated areas (*). (B) Staining in undifferentiated cells, mainly located in the
invasive front of tumor tissue. (C) Staining in differentiated cells located at the center of the tumor islands.
3.3. Associations of ZFAND4 with Clinicopathologic Characteristics
We next assessed the correlations of high ZFAND4 expression with the clinical data. Table 2
shows the associations of high ZFAND4 expression determined by using the maximum value of
the percentage of stai e cells to calculate the Allred score. In differentiated areas, high ZFAND4
expression was significantly associated with wel - tiated (p = .04) and on-recurrent tumors
(p = 0.04), whereas ZFAND4 expression in undiff i ted cells wa significantly corr lated with
tumor location in the tongue (p = 0.005).
On the other hand, when the Allred score was calculated using the mean value of percentage
of stained cells (Table 3), ZFAND4 expression in differentiated cells was found to be significantly
associated with N status (p = 0.02), being more frequently detected in pN0 and pN1 cases compared to
pN2. Howeve , no significant relationship was found between ZFAND4 expression in undifferentiated
cells and any clinicopathologic variable.
Table 2. Relationships between clinical and pathological variables and high ZFAND4 expression
determined by using the maximum value of stained cells to calculate the Allred score.
Variable Number ofCases
High ZFAND4 Expression in
Undifferentiated Cells (%) p
High ZFAND4 Expression in
Differentiated Cells (%)
Gender
0.98Men 81 50 (62) 38 (47)
Women 42 26 (62) 17 (40)
Tobacco use
0.77Smoker 83 52 (63) 34 (41)
Non-smoker 40 24 (60) 21 (52)
Alcohol use
0.99Drinker 68 42 (62) 31 (46)
Non-drinker 55 34 (62) 24 (44)
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Table 2. Cont.
Variable Number ofCases
High ZFAND4 Expression in
Undifferentiated Cells (%) p
High ZFAND4 Expression in
Differentiated Cells (%)
pT
0.44
pT1 27 19 (70) 16 (59)
pT2 53 33 (62) 25 (47)
pT3 15 10 (67) 4 (27)
pT4 28 14 (50) 10 (36)
pN
0.75
pN0 74 45 (61) 34 (46)
pN1 25 17 (68) 13 (52)
pN2 24 14 (58) 8 (33)
Clinical stage
0.69
Stage I 20 13 (65) 9 (45)
Stage II 31 20 (64) 16 (52)
Stage III 25 17 (68) 11 (44)
Stage IV 47 26 (55) 19 (40)
G status
0.14G1 (Well) 78 52 (67) 40 (51)
G2 + G3 (Moderate + poor) 45 24 (53) 15 (33)
Tumor location
0.005Tongue 51 39 (76) 23 (45)
Rest 72 37 (51) 32 (44)
Tumor location
0.5Floor of the mouth 35 20 (57) 16 (46)
Rest 88 56 (64) 39 (44)
Tumor recurrence
0.61No 69 44 (64) 36 (52)
Yes 54 32 (59) 19 (35)
Second primary carcinoma
0.89No 104 64 (61) 48 (46)
Yes 19 12 (63) 7 (37)
Clinical status at the end of
the follow-up
0.73Live and without recurrence 51 32 (63) 26 (51)
Dead of index cancer 53 31 (58) 20 (38)
Lost or died of other causes 19 13 (68) 9 (47)
Table 3. Relationships between clinical and pathological variables and high ZFAND4 expression
determined by using the mean value of stained cells to calculate the Allred score.
Variable Number ofCases
High ZFAND4
Expression in
Undifferentiated
Cells (%)
p
High ZFAND4
Expression in
Differentiated
Cells (%)
p
Gender
0.95 0.33Men 81 42 (52) 26 (32)
Women 42 22 (52) 10 (24)
Tobacco use
0.75 0.58Smoker 83 44 (53) 23 (28)
Non-smoker 40 20 (50) 13 (32)
Alcohol use
0.89 0.21Drinker 68 35 (51) 23 (34)
Non-drinker 55 29 (53) 13 (24)
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Table 3. Cont.
Variable Number ofCases
High ZFAND4
Expression in
Undifferentiated
Cells (%)
p
High ZFAND4
Expression in
Differentiated
Cells (%)
p
pT
0.29 0.33
pT1 27 16 (59) 11 (41)
pT2 53 27 (51) 15 (28)
pT3 15 10 (67) 2 (13)
pT4 28 11 (39) 8 (29)
pN
0.85 0.02
pN0 74 37 (50) 24 (32)
pN1 25 14 (56) 10 (40)
pN2 24 13 (54) 2 (8)
Clinical stage
0.46 0.81
Stage I 20 10 (50) 6 (30)
Stage II 31 17 (55) 11 (35)
Stage III 25 16 (64) 9 (36)
Stage IV 47 21 (45) 10 (21)
G status
0.36 0.08G1 (Well) 78 43 (55) 27 (35)
G2 + G3 (Moderate + poor) 45 21 (47) 9 (20)
Tumor location
0.1 0.43Tongue 51 31 (61) 13 (25)
Rest 72 33 (46) 23 (32)
Tumor location
0.75 0.44Floor of the mouth 35 19 (54) 12 (34)
Rest 88 45 (51) 24 (27)
Tumor recurrence
0.97 0.47No 69 36 (52) 22 (32)
Yes 54 28 (52) 14 (26)
Second primary carcinoma
0.29 0.75No 104 52 (50) 31 (30)
Yes 19 12 (63) 5 (26)
Clinical status at the end of
the follow-up
0.85 0.59Live and without recurrence 51 26 (51) 17 (33)
Dead of index cancer 53 27 (51) 15 (28)
Lost or died of other causes 19 11 (58) 4 (21)
3.4. ZFAND4 Expression and Patients’ Survival
Over a median follow-up period of 61 months, 27 patients (42.1%) harboring high ZFAND4
expression in undifferentiated cells calculated by using the mean Allred score died due to the index
cancer, and 15 patients (41.6%) with high ZFAND4 expression in the differentiated cells. When
the maximum Allred score was used, 31 patients (40.7%) with high ZFAND4 expression in the
undifferentiated cells, and 20 patients (36.3%) with high ZFAND4 expression in the differentiated
cells died due to the index cancer. Kaplan-Meier analysis showed that there were no statistically
significant differences in disease-specific survival (DSS) between patients with high versus low
ZFAND4 expression in either differentiated or undifferentiated cells (Table 4).
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Table 4. Univariate Kaplan-Meier and Cox analysis to assess the association of ZFAND4 expression on disease-specific survival in oral squamous cell carcinoma patients.
ZFAND4 Expression Censored Patients (%) Mean Survival Time (95% CI) HR (95% CI) p
Undifferentiated cells
0.7
calculated by using the mean Allred score
Low 33 (56) 107.72 (86.32–129.12) Reference
High 37 (58) 135.20 (108.87–161.52) 0.90 (0.52–1.55)
Differentiated cells
0.8
calculated by using the mean Allred score
Low 49 (56) 126.62 (104.38–148.85) Reference
High 21 (58) 135.11 (99.60–170.62) 0.93 (0.51–1.69)
Undifferentiated cells
0.53
calculated by using the maximum Allred score
Low 25 (53) 104.14 (80.46–127.82) Reference
High 45 (59) 136.44 (111.81–161.06) 0.84 (0.48–1.45)
Differentiated cells
0.25
calculated by using the maximum Allred score
Low 35 (51) 105.55 (85.11–126.00) Reference
High 35 (64) 144.08 (114.95–173.21) 0.72 (0.41–1.26)
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4. Discussion
This study aimed to investigate the clinical relevance and prognostic significance of ZFAND4 in
OSCC. The prevalence of OSCC is estimated at 264,000 cases and 128,000 deaths annually worldwide [3].
Since the completion of the Human Genome Project in 2003, the subsequent progress in understanding
the biology of cancer has led to the development of personalized therapies based on the patient’s
unique molecular and genetic profile to target defective signaling pathways of tumor cells. It is
generally accepted that OSCC arises from multiple genetic alterations, although the molecular basis
of carcinogenesis is not fully understood. DNA sequencing technologies coupled with advances in
algorithms have enormously contributed to the molecular and functional characterization of mutations,
genes, and pathways altered in multiple cancers, including OSCC [9–12]. Furthermore, the majority of
tumors showed alterations in multiple targetable genes that are candidates for combination therapy [11].
It is of paramount importance to identify molecular alterations involved in the development of
recurrent and metastatic disease, which remains the main cause of morbidity and mortality in
OSCC patients.
In a recent paper, Sasahira et al. [5] conducted a cDNA microarray analysis in order to compare
the gene expression profile of primary and recurrent OSCC. Ten genes were found to be upregulated in
recurrent OSCC compared with the primary tumors. Among these genes, ZFAND4 showed a 100-fold
recurrent/primary, thus suggesting a possible role for this gene in tumorigenesis. Tang et al. [7]
reported that ZFAND4 expression was consistently highly expressed in gastric cancer compared to
normal tissue, and positively associated with increased stage. Functionally, ZFAND4 was found
to downregulate the expression of the anti-proliferative miRNAs, miR-148b, miR-375, and miR-182,
in SGC-7901 cells, thereby promoting cell proliferation by activation of cyclin-dependent kinase and
downregulation of p21 and p53 [7], which supports the notion that ZFAND4 may act as an oncogene
in gastric cancer.
In this study, we assumed the same methodology used by Kurihara-Shimomura et al. [6] in
order to validate their results in an independent cohort of OSCC patients, and more importantly,
the utility of ZFAND4 as a predictor of metastasis and poor prognostic marker. Interestingly, ZFAND4
staining consistently showed distinct expression patterns and distribution in our cohort of 125 OSCC,
i.e., granular staining in undifferentiated areas and diffuse staining in differentiated areas of the tumors.
These two expression patterns were analyzed separately to evaluate possible correlations with the
clinical and follow-up data. Moreover, Allred scores were calculated using both maximum value and
mean value of ZFAND4-positive cells for the three tissue cores selected from each tumor.
We found that ZFAND4 staining was higher in undifferentiated than in differentiated areas of
tumors. However, ZFAND4 expression in differentiated cells showed the most relevant and significant
associations with well-differentiated (p = 0.04) and non-recurrent tumors (p = 0.04). Nevertheless,
ZFAND4 expression did not show a major impact on patient survival. Only a trend was observed
between low ZFAND4 expression in differentiated cells and tumor-associated deaths (Table 4).
Therefore, the prognostic relevance of ZFAND4 described by Kurihara-Shimomura et al. [6] has
not been replicated in our series. Furthermore, Kurihara-Shimomura et al. [6] reported that ZFAND4 is
essential for distant metastasis in OSCC, and hypothesized that ZFAND4 could facilitate metastasis to
the lymph nodes and distant organs by promoting angiogenesis and/or lymphangiogenesis. In marked
contrast, our results only proved a marginal (if any) relationship between ZFAND4 expression and
the presence of lymph node metastasis. The limitations of our study are the retrospective design
and the use of tissue microarrays to evaluate ZFAND4 immunostaining. Several factors could
contribute to the discrepant results between these two studies. On one hand, etiological, clinical,
and epidemiological differences in the patient cohorts as well as molecular/biological differences
among tumors depending on the geographic areas. Moreover, ZFAND4 expression exhibited a highly
heterogeneous pattern within the tumors depending on the differentiation status, which could certainly
have a major contribution on the varying results. Particularly since we evaluated separately the clinical
significance and correlations of the two distinct ZFAND4 expression patterns in undifferentiated and
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differentiated areas of tumors, while Kurihara-Shimomura et al. [6] did not distinguish expression
patterns within the different tumor areas. Thus, positive ZFAND4 immunostaining was scored in
the whole tumor as the diffuse staining in tumor islands, cords, or sheets, irrespective of the cell
differentiation status and the grade of keratinization. Since ZFAND4 expression showed two distinct
non-overlapping expression patterns depending on the differentiation areas of tumors, each with
a clearly distinct clinical significance, evaluation of ZFAND4 expression in the whole tumor could
therefore be misleading.
5. Conclusions
The herein presented data question the clinical relevance of ZFAND4 expression as a prognostic
biomarker in OSCC, and also revealed distinct ZFAND4 expression patterns depending on the
differentiation areas of tumors that should be evaluated separately. Further studies are necessary to
fully elucidate the pathobiological role of ZFAND4 in OSCC and the potential clinical implications.
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